Vanda Pharmaceuticals (VNDA) Q3 2024 earnings summary

Executive summary

• Q3 2024 saw commercial launches of Fanapt for bipolar I disorder and Ponvory for multiple sclerosis, supported by a significantly expanded sales force and strong early adoption, with Fanapt new patient starts up over 90% year-over-year.

• Ponvory transition from Janssen completed, with positive prescriber and patient feedback and plans for indication expansion in autoimmune disorders.

• HETLIOZ faces ongoing generic competition, with net product sales expected to decline and multiple ongoing lawsuits and regulatory actions.

• FDA declined to approve tradipitant for gastroparesis in September 2024; NDA for milsaperidone planned for early 2025, and new clinical programs for tradipitant and HETLIOZ underway.

• R&D pipeline includes late-stage and early-stage programs in psychiatry, neurology, and rare diseases.

Financial highlights

• Q3 2024 total revenue was $47.7M, up 23% year-over-year but down 6% sequentially from Q2 2024.

• Fanapt Q3 sales were $23.9M, up 12% year-over-year and 3% sequentially; HETLIOZ sales were $17.9M, up 2% year-over-year but down 4% sequentially; Ponvory sales were $5.9M, down 32% sequentially due to inventory destocking.

• Net loss for Q3 2024 was $5.3M versus net income of $0.1M in Q3 2023; operating expenses rose to $58.7M from $44.8M year-over-year.

• Cash and equivalents at September 30, 2024, were $376.3M, not including an $8.1M payment received in Q4.

• Gross margin remained strong with cost of goods sold at $2.6M in Q3 2024.

Outlook and guidance

• 2024 net product sales guidance raised to $190M–$210M; year-end cash guidance raised to $370M–$390M.

• Full commercial infrastructure for Fanapt and Ponvory expected by year-end, with revenue impact anticipated to grow in late 2024 and into 2025.

• Cash resources expected to be sufficient for at least the next 12 months based on current operating plans.

• NDA submissions planned for milsaperidone (early 2025) and tradipitant for motion sickness (Q4 2024); IND filings for Ponvory in psoriasis and ulcerative colitis expected in Q4 2024.